Hjem
Øystein Fluges bilde

Øystein Fluge

Professor
  • E-postOystein.Fluge@uib.no
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • 2020. Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress. Bone Marrow Transplantation. 1-3.
  • 2020. Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue. PLOS ONE.
  • 2020. Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study. Frontiers in medicine.
  • 2020. Human Leukocyte Antigen Alleles Associated With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Scientific Reports. 1-8.
  • 2019. Upregulated PDK4 expression is a sensitive marker of increased fatty acid oxidation. Mitochondrion (Amsterdam. Print). 97-110.
  • 2019. Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma. Acta Oncologica. 1315-1322.
  • 2019. Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation. Bone Marrow Transplantation. 1-15.
  • 2019. Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome. Clinical Therapeutics. 836-847.
  • 2019. No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology. 1-7.
  • 2019. Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes. Acta Oncologica. 690-699.
  • 2019. B-lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 585-593.
  • 2018. Rituximab serum concentrations and anti-rituximab antibodies during B-cell depletion therapy for myalgic encephalopathy/chronic fatigue syndrome. Clinical Therapeutics. 9.
  • 2018. Immunosignature Analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Molecular Neurobiology. 1-9.
  • 2018. Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity. Bone Marrow Transplantation. 1-4.
  • 2017. Extranodal NK/T-cell lymphoma, nasal type, primarily involving ovary. Human Pathology: Case Reports. 58-60.
  • 2017. Consolidative radiotherapy to residual masses after chemotherapy is associated with improved outcome in diffuse large B-cell lymphoma. A retrospective, population-based study. Clinical Lymphoma, Myeloma & Leukemia. 125-135.
  • 2016. Serum BAFF and APRIL levels, T-lymphocyte subsets, and immunoglobulins after B-cell depletion using the monoclonal anti-CD20 antibody rituximab in myalgic encephalopathy/chronic fatigue syndrome. PLOS ONE.
  • 2016. Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation. Acta Oncologica. 547-553.
  • 2016. Multimodal therapy is feasible in elderly anal cancer patients. Acta Oncologica. 81-87.
  • 2016. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight.
  • 2016. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. JCI Insight.
  • 2016. Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain, behavior, and immunity. 32-39.
  • 2016. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma. British Journal of Haematology. 432-443.
  • 2015. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica. 534-540.
  • 2015. Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway. Haematologica. e240-e243.
  • 2015. B-lymphocyte depletion in myalgic encephalopathy/chronic fatigue syndrome. An open-label phase II study with rituximab maintenance treatment. PLOS ONE.
  • 2014. Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma. PLOS ONE.
  • 2013. Pseudoprogression in high-grade glioma. Acta Neurologica Scandinavica. 31-37.
  • 2013. High dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008. Tidsskrift for Den norske legeforening. 1704-1709.
  • 2013. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of Oncology. 1385-1392.
  • 2012. High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. European Journal of Haematology. 395-402.
  • 2012. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. British Journal of Cancer. 1684-1691.
  • 2012. Expression of DSG1 and DSC1 are prognostic markers in anal carcinoma patients. British Journal of Cancer. 756-762.
  • 2011. MicroRNA-15b is induced with E2F-controlled genes in HPV-related cancer. British Journal of Cancer. 1719-1725.
  • 2011. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. British Journal of Haematology. 600-610.
  • 2011. Benefit from B-lymphocyte depletion using the anti-CD20 antibody rituximab in chronic fatigue syndrome. A double-blind and placebo-controlled study. PLOS ONE. 13 sider.
  • 2010. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of Neuro-Oncology. 393-402.
  • 2009. Kinetics study on markers of the immune system by gene expression profiling of an in vivo heated tumor. International Journal of Hyperthermia. 41-46.
  • 2009. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncologica. 368-376.
  • 2009. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. British Journal of Cancer. 1282-1289.
  • 2009. Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series. BMC Neurology. 7 sider.
  • 2008. Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour. Radiotherapy and Oncology. 435-442.
  • 2008. Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model. International Journal of Hyperthermia. 425-441.
  • 2008. Gene expression reveals two distinct groups of anal carcinomas with clinical implications. British Journal of Cancer. 1264-1273.
  • 2008. Current status of antivascular therapy and targeted treatment in the clinic. International Journal of Hyperthermia. 97-110.
  • 2006. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 161-175.
  • 1998. Hospitalization for lung disease in early childhood and asthma symptoms in young adulthood. Respiratory Medicine. 1003-1009.
  • 1998. Fish consumption and respiratory symptoms among young adults in a Norwegian community. European Respiratory Journal. 336-340.
Leserinnlegg
  • 2018. Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon . Tidsskrift for Den norske legeforening. 12-13.
  • 2017. Mer om pyruvat dehydrogenase og kronisk utmattelsessyndrom. Tidsskrift for Den norske legeforening.
  • 2017. Chronic fatigue syndrome and pyruvate dehydrogenase function. Tidsskrift for Den norske legeforening.
Vitenskapelig kommentarutgave
  • 2018. Kronisk utmattelsessyndrom og pyruvat dehydrogenasefunksjon.
Doktorgradsavhandling
  • 2004. Gene expression in papillary thyroid carcinomas, with special reference to tyrosine kinase receptors and growth factors.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • 2009. Kreftceller og kjemoterapi. 25 sider.
  • 2006. Thyroid Cancer: Molecular Biology and Clinical Aspects. 14 sider.
Sammendrag/abstract
  • 2012. Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma. Journal of Clinical Oncology. 1 sider.
  • 2011. (18)FDG PET/CT AFTER INTENSIFIED CHEMO-IMMUNOTHERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), AGED 18-65 YEARS WITH AAIPI 2-3. POSITIVE OR INDETERMINATE LESIONS HAVE A LOW POSITIVE PREDICTIVE VALUE. A NORDIC PHASE II SUBSTUDY. Annals of Oncology. 159-159.
  • 2010. R-CHOEP-14 x 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years. Blood. 1157-1157.
  • 2010. High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Dose-Dense Chemoimmunotherapy and Systemic CNS Prophylaxis. Results From a Nordic Phase II Study. Blood. 1686-1686.
  • 2010. Exon-Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B-Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmuno-therapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. Blood. 1281-1281.
  • 2010. Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell/Follicular Grade 3 Lymphoma Patients Treated with Dose-Dense Chemoimmuno-therapy and CNS Prophylaxis. Results From a Nordic Lymphoma Group Phase II Study. Blood. 1281-1281.
Vitenskapelig oversiktsartikkel/review
  • 2008. Analkreft. 198-200.
Faglig kapittel
  • 2016. Kreftbiologi og medikamentell terapi. 13-46. I:
    • 2016. Medikamentell kreftbehandling - Cytostatikaboken 8. utgave 2016. Avdeling for farmakologi, Universitetet i Oslo.

Se fullstendig oversikt over publikasjoner i CRIStin.